[Form 4] Akari Therapeutics plc ADR (0.01 USD) Insider Trading Activity

Rhea-AI Filing Summary

Akari Therapeutics plc (NASDAQ: AKTX) – Form 4 insider transaction

On 06/20/2025, President & Chief Executive Officer Abizer Gaslightwala, who also serves as a director of the company, purchased 10,000 American Depositary Shares (ADS) of Akari Therapeutics in an open-market transaction. The shares were acquired at a price of $1.20 per ADS, for an aggregate consideration of approximately $12,000.

Following the purchase, the reporting person’s direct holding increased to 271,428 ADS. Each ADS represents 2,000 ordinary shares of Akari Therapeutics with a par value of $0.0001 per ordinary share, as noted in the footnote to the filing.

No dispositions were reported, and the filing shows no derivative security transactions. The form was signed by Torsten Hombeck, acting as attorney-in-fact, on 06/24/2025.

This Form 4 therefore documents a single, straightforward insider purchase by the company’s most senior executive, with no accompanying sales or option exercises disclosed.

Insights

Financial Analyst

TL;DR: CEO bought 10k ADS at $1.20; small, single insider buy—neutral impact.

The filing records a direct, open-market purchase by Akari’s CEO. While insider buying by the top executive is generally viewed favourably, the $12k size is modest relative to typical materiality thresholds. No other executives participated and no derivatives were involved. The transaction marginally lifts the CEO’s stake to 271,428 ADS, signalling continuing alignment but not a transformational change in ownership. With no concurrent earnings or strategic disclosures, the market impact is likely limited.

Corporate Governance Expert

TL;DR: Governance-positive signal from CEO, but scale too small to alter oversight view.

From a governance lens, a CEO personally adding shares is directionally positive, underscoring commitment to shareholder value. However, best-practice guidelines look for more substantial dollar commitments to classify such trades as strongly indicative. The absence of a 10b5-1 plan box suggests discretionary timing, which the market may scrutinise for signalling intent, yet the low dollar value tempers that scrutiny. Overall, the filing neither raises red flags nor meaningfully strengthens governance metrics.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gaslightwala Abizer

(Last) (First) (Middle)

C/O AKARI THERAPEUTICS PLC

22 BOSTON WHARF ROAD FL 7

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Akari Therapeutics Plc [ AKTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
American Depositary Shares representing Ordinary Shares(1)	06/20/2025		P		10,000	A	$1.2	271,428	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer.

	/s/ Torsten Hombeck, as Attorney-in-Fact	06/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Akari Therapeutics (AKTX) ADS did CEO Abizer Gaslightwala purchase?

10,000 ADS were purchased on 06/20/2025.

What was the purchase price per ADS in the Form 4 filing?

The shares were bought at $1.20 per ADS.

What is the CEO’s total direct holding after the reported transaction?

Following the transaction, Abizer Gaslightwala owns 271,428 ADS directly.

Were any derivative securities reported in this Form 4?

No. The filing shows no derivative security acquisitions or dispositions.

How many ordinary shares does one Akari Therapeutics ADS represent?

Each ADS equals 2,000 ordinary shares of Akari Therapeutics.